Detalles de la búsqueda
1.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27979383
2.
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Thorac Cancer
; 13(3): 483-488, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34939342
3.
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
J Thorac Oncol
; 16(1): 140-150, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33166718
4.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Eur J Cancer
; 150: 224-231, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33934059
5.
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Eur J Cancer
; 148: 24-35, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721704
6.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Thorac Cancer
; 12(6): 880-889, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33527756
7.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827906
8.
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
Clin Lung Cancer
; 21(1): 15-20, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31607443
9.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
J Immunother Cancer
; 8(2)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33077515
10.
Editorial: Small cell lung cancer: New drugs and strategies.
Front Med (Lausanne)
; 10: 1140642, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36778741
11.
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol
; 13(8): 1156-1170, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29777823
12.
Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR.
Glob Reg Health Technol Assess
; 9: 22-29, 2022.
Artículo
en Italiano
| MEDLINE | ID: mdl-36628318
13.
Focus on Nivolumab in NSCLC.
Front Med (Lausanne)
; 3: 67, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-28018902
14.
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
J Thorac Oncol
; 5(10): 1662-3, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20871265
15.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Lancet
; 389: 255-265, enero, 2017.
Artículo
en Inglés
| URUCAN | ID: bcc-5147
Resultados
1 -
15
de 15
1
Próxima >
>>